Chas Pulido is an accomplished investor and entrepreneur with a focus on advancing human health through innovative life science ventures. As the Founder and General Partner of Alix Ventures since 2020, Chas has supported early-stage startups pioneering engineering biology for patient impact. Chas also serves as an investor in multiple companies, including Mythic Therapeutics, Strand Therapeutics, and ELEGEN, among others, demonstrating a commitment to enhancing therapeutic effectiveness and technology-driven health solutions. Chas's educational background includes Y Combinator, the University of Notre Dame - Mendoza College of Business, and The Bishop's School.